Newsroom | 51722 results

WASHINGTON--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory ("JBL"), the Tokyo-based developer and manufacturer of the Tokyo strain of BCG (Tokyo-172 BCG). The agreement provides ImmunityBio exclusive U.S. rights to develop, import, and commercialize intravesical Tokyo-172 BCG. JBL's Tokyo strain of BCG is supported by the February 2026 positive Phase III rea...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively. In the neoadjuvant setting, ENHERTU followed by a taxane, trastuzumab, and pertuzumab (THP) has been approved for the treatment of...

TOKYO--(BUSINESS WIRE)--Enhertu Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in patients with treatment-refractory hepatocellular carcinoma (HCC) who had progressed following prior immunotherapy. The manuscript, titled “A phase 1b study of botensilimab and balstilimab in treatment-refractory h...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on May 14, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stoc...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to four individuals whose employment commenced in either March 2026 or April 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 24,50...

DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), un'azienda farmaceutica globale con la missione di fornire farmaci e soluzioni efficaci per una vita quotidiana più sana, presenterà dati relativi alla salute delle donne, ai biosimilari, alla dermatologia e alla neurologia in occasione di ISPOR 2026, il principale convegno scientifico mondiale organizzato dalla Società Internazionale di Farmacoeconomia e Ricerca sui Risultati. La conferenza, incentrata sull'economia sanitaria e la ricerc...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), een wereldwijd actief gezondheidszorgbedrijf met als missie het leveren van effectieve geneesmiddelen en oplossingen voor een gezonder dagelijks leven, presenteert gegevens over vrouwengezondheid, biosimilars, dermatologie en neurologie op ISPOR 2026, de toonaangevende internationale wetenschappelijke conferentie van de International Society for Pharmacoeconomics and Outcomes Research. De conferentie, gericht op gezondheidseconomie en uit...